DNA profiling of primary serous ovarian and Fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification

Journal of Pathology

Volumn 213, Issue 1, 2007, Pages 46-55

  Nowee, M E ^a   Snijders, A M ^b   Rockx, D A P ^a   de Wit, R M ^a   Kosma, V M ^d,e   Hamalainen K ^d,e   Schouten, J P ^f   Verheijen, R H M ^a   van Diest, P J ^g   Albertson, D G ^b,c   Dorsman, J C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f MRC HOLLAND   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Array CGH; Fallopian tube carcinoma; MLPA; Ovarian carcinoma; Serous adenocarcinoma

Indexed keywords

ACTN4 PROTEIN; BCAS4 PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CCNE1 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVI1 PROTEIN; FOCAL ADHESION KINASE 1; INITIATION FACTOR; INITIATION FACTOR 2C2; MICRORNA; MTSS1 PROTEIN; MYC PROTEIN; ONCOPROTEIN; PROTEIN KINASE B; PSMB4 PROTEIN; SPINT2 PROTEIN; TEAD4 PROTEIN; TSPAN9 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 12P; CHROMOSOME 19Q; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 8Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; INDIVIDUALIZATION; MOLECULAR PROBE; OVARY CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; UTERINE TUBE CARCINOMA; CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; DNA FINGERPRINTING; DNA MICROARRAY; DNA PROBE; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MOLECULAR GENETICS; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID HYBRIDIZATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; UTERINE TUBE TUMOR;

BASE SEQUENCE; CARCINOMA; CYSTADENOCARCINOMA, SEROUS; DNA FINGERPRINTING; DNA PROBES; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID AMPLIFICATION TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS;

EID: 34548433549     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2217     Document Type: Article

References (50)

1. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol 2005;36:861-870.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-2529.
3. Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000; 76:45-50.
4. Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341-345.
5. Colgan TJ. Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol 2003;22:109-120.
6. Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS. Primary fallopian tube carcinoma. Obstet Gynecol Surv 2005;60:247-252.
7. Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol 2003;90:491.
8. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, et al. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 2003;88:SI6-21.
9. Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 2003;63:417-423.
10. Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res 2002;62:3466-3476.
11. Israeli O, Goldring-Aviram A, Rienstein S, Ben Baruch G, Korach J, Goldman B, et al. In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet 2005;160:35-42.
12. Heselmeyer K, Hellstrom AC, Blegen H, Schrock E, Silfversward C, Shah K, et al. Primary carcinoma of the fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations. Int J Gynecol Pathol 1998;17:245-254.
13. Pere H, Tapper J, Seppala M, Knuutila S, Butzow R. Genomic alterations in fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis. Cancer Res 1998;58:4274-4276.
14. Davies JJ, Wilson IM, Lain WL. Array CGH technologies and their applications to cancer genomes. Chromosome Res 2005; 13:237-248.
15. Pinkel D, Albertson DG. Array comparative genomic hybridization and its applications in cancer. Nat Genet 2005;37(suppl):S11-17.
16. Bernardini M, Weberpals J, Squire JA. The use of cytogenetics in understanding ovarian cancer. Biomed Pharmacother 2004; 58:17-23.
17. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003;163:985-992.
18. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004;10:1251-1256.
19. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 2005; 7:603-613.
20. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, et al. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 2004;155:97-107.
21. Tapper J, Butzow R, Wahlstrom T, Seppala M, Knuutila S. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 1997; 75:1782-1787.
22. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164:1511-1518.
23. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30:e57.
24. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003.
25. Hu CY, Taymor ML, Hertig AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950;59:58-67.
26. Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am 1978;58:121-129.
27. Weiss MM, Hermsen MA, Meijer GA, van Grieken NC, Baak JP, Kuipers EJ, et al. Comparative genomic hybridisation. Mol Pathol 1999; 52:243-251.
28. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-264.
29. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005;24:4232-4242.
30. Snijders AM, Nowee ME, Fridlyand J, Piek JM, Dorsman JC, Jain AN, et al. Genome-wide array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 2003; 22:4281-4286.
31. Purnomosari D, Aryandono T, Setiaji K, Nugraha SB, Pals G, van Diest PJ. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer. Biotech Histochem 2006;81:79-85.
32. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Lohrs U, et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 2006;126:101-109.
33. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
34. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFβ-and taxol-mediated cell death via PI3K/AKT. Oncogene 2006;25:3565-3575.
35. Kumar CC. Signaling by integrin receptors. Oncogene 1998; 17:1365-1373.
36. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002;1:53-62.
37. Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006; 66:8949-8953.
38. Berglund P, Landberg G. Cyclin e over-expression reduces infiltrative growth in breast cancer: yet another link between proliferation control and tumor invasion. Cell Cycle 2006;5:606-609.
39. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 2001;293:1146-1150.
40. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. MicroRNAs; exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006;103:9136-9141.
41. Lee YG, Macoska JA, Korenchuk S, Pienta KJ. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 2002; 4:291-294.
42. Bompard G, Sharp SJ, Freiss G, Machesky LM. Involvement of Rac in actin cytoskeleton rearrangements induced by MIM-B. J Cell Sci 2005; 118:5393-5403.
43. Hsu DK, Guo Y, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, et al. Identification of a murine TEF-1-related gene expressed after mitogenic stimulation of quiescent fibroblasts and during myogenic differentiation. J Biol Chem 1996;271:13786-13795.
44. Zoller M. Gastrointestinal tumors: metastasis and tetraspanins. Z Gastroenterol 2006;44:573-586.
45. Gutierrez GM, Kong E, Hinds PW. Master or slave: the complex relationship of RBP2 and pRb. Cancer Cell 2005;7:501-502.
46. Kornberg U, Villaret D, Popp M, Lui L, McLaren R, Brown H, et al. Gene expression profiling in squamous cell carcinoma of the oral cavity shows abnormalities in several signaling pathways. Laryngoscope 2005;115:690-698.
47. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. c-erbB-2/neu over-expression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 1994;54:3260-3266,
48. Nagaike K, Kohama, K, Uchiyama S, Tanaka H, Chijiiwa K, Itoh H, et al. Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci 2004;95:728-735.
49. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005; 128:51-62.
50. Pick JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko, FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-456.